NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for BioMarin Pharmaceutical


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
Aceras BioMedical Portfolio Company Acquired by BioMarin
2009 NOV 9 ... LLC (Aceras), has sold Huxley Pharmaceuticals Inc. (Huxley), a portfolio company, to BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Huxley was established by Aceras in August 2008 with a focus on ...
Subject: Rodman & Renshaw Capital Group, Inc.
Price: $3.00
*
BioMarin Acquires Huxley Pharmaceuticals, Inc.
2009 NOV 10 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), ...
Subject: Autoimmune Disease
Price: $3.00
*
BioMarin Announces Second Quarter 2009 Financial Results
2009 AUG 10 ... on the future of the 6R-BH4 PAH program in the second half of Keywords: BioMarin Pharmaceutical Inc., U.S. Food and Drug Administration, FDA, Clinical Trial Research This ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin Announces Third Quarter 2009 Financial Results
2009 NOV 9 ... and frequency optimization and an extension period. Results from Keywords: BioMarin Pharmaceutical Inc., Clinical Trial Research This article was prepared by Biotech Business ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
2009 OCT 5 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the first patient has initiated treatment in the Phase ...
Subject: Clinical Trial Research
Price: $3.00
*
BioMarin to Present at the Baird Healthcare Conference
2009 SEP 15 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Hank Fuchs, M.D., Senior Vice President and Chief ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin to Present at the Credit Suisse Healthcare Conference
2009 NOV 16 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Jean-Jacques Bienaime, Chief Executive Officer of ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin to Present at the Jefferies Healthcare Conference
2009 JUN 23 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Steve Aselage, Senior Vice President and Chief ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin to Present at the Morgan Stanley Healthcare Conference
2009 SEP 22 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Jean-Jacques Bienaime, Chief Executive Officer of ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin to Present at the Oppenheimer Healthcare Conference
2009 NOV 10 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Hank Fuchs, M.D., Chief Medical Officer of BioMarin, ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin to Present at the UBS Global Life Sciences Conference
2009 SEP 29 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Jean-Jacques Bienaime, Chief Executive Officer of ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
BioMarin's Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
2009 OCT 19 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that its Chief Executive Officer Jean-Jacques Bienaime will ...
Subject: Pharmaceuticals
Price: $3.00
*
Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
2009 AUG 31 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that data from clinical studies of Kuvan (sapropterin ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
Marc J. Fagel of the U.S. Securities and Exchange Commission to Discuss SEC Enforcement at CBI's Biotech/Pharma Finance and Accounting Forum in San Francisco
2009 OCT 19 ... to the SEC, will include presentations from firms such as Cell Genesys, Affymax, BioMarin Pharmaceuticals, Monogram Biosciences, Inc., Oncomed and Poniard Pharmaceuticals. Over ... Inc., Oncomed and Poniard Pharmaceuticals. Over 2,400 executives have attended CBI's Pharmaceutical Accounting and Financial Reporting Congress since its inception more than five years ...
Subject: Biotech Business
Price: $3.00
*
Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme
2009 NOV 23 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that Genzyme notified the company that, in rare ...
Subject: BioMarin Pharmaceutical Inc.
Price: $3.00
*
Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio a Syndrome
2009 JUL 27 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that patient enrollment has been completed for the Phase ...
Subject: Clinical Trial Research
Price: $3.00
*
Richard A. Meier Appointed to STAAR Surgical Board of Directors
2009 JUL 7 ... and management positions at other firms. Mr. Meier currently serves as a Director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a company which develops and commercializes innovative ...
Subject: Staar Surgical Company
Price: $3.00
*
United States Patent Office Allows Claims Covering the Approved Administration of Kuvan with Food
2009 OCT 12 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the United States Patent and Trademark Office has ...
Subject: Patents
Price: $3.00
*
United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food
2009 NOV 16 ... BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that the United States Patent and Trademark Office has ...
Subject: Patents
Price: $3.00
*
William Aliski Named FoldRx Chief Commercial Officer
2009 JUN 22 ... Aliski spent two years working in London as the Vice President and General Manager of Biomarin Europe, where he helped establish the company and initiated commercial operations to ... Keywords: Enzyme Therapy, Health, Biotechnology, Cardiology, Clinical Trials, Pharmaceutical, Marketing, AdvertisingAmyloidosis, Bioengineering, Biomedical Engineering, Biomedicine, ...
Subject: FoldRx Pharmaceuticals, Inc.
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login